Navigation Links
China Sky One Medical Announces Antroquinonol Capsule Recognized as Breakthrough Drug by Chinese Ministry of Science and Technology

HARBIN, China, March 18 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced that Antroquinonol (Hocena) capsule, a new anti-cancer drug co-developed by Taiwan Golden Biotechnology Corporation ("Golden Biotech") was recognized as Breakthrough Drug by the Chinese Ministry of Science and Technology.

In order to promote innovation within the Chinese pharmaceutical industry, the Chinese Ministry of Science and Technology (MoST) and Chinese Ministry of Health (MoH) launched a project to support the research and development of breakthrough drugs which are used to treat cancer, AIDS, and cardio- and cerebro-vascular diseases. The government will not only accelerate the processing of new drug applications but also provide financial and technical support for these breakthrough drugs.

"We are honored to receive this recognition and we appreciate the government's support for our R&D efforts, which reinforces our commitment to expand our drug portfolio and develop high-value drugs. The Antroquinonol capsule is the first drug to be recognized as Breakthrough Drug in the Heilongjiang Province. We anticipate its research progress and new drug application procedures will be greatly shortened. We look forward to receiving the approval to enter into clinical trial within one year and we hope to receive SFDA final approval for production within three years," said Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical.

In May 2009, the Company signed an agreement with Taiwan Golden Biotechnology Corporation to begin cooperating on the development of Antroquinonol, which is a kind of compound extracted from Antrodia Cinnamomea Chang & Chou, a rare medicinal fungus that grows naturally inside the Cinnamonum kanehirae tree trunk, a native tree species of Taiwan. It can be used in the treatment of liver cancer and lung cancer. Antroquinonol has been approved by the U.S. FDA to enter into first stage clinical trial.

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR"), Harbin First Bio-Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include expectations of the effect of government support and the R&D progress of new drugs. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

    For more information, please contact:

    Company Contact:
     China Sky One Medical, Inc.
     Mr. Stanley Hao, CFO
     Tel:   +86-451-8703-2617

    Investor Relations Contact:
     CCG Investor Relations
     Ms. Lei Huang, Account Manager
     Tel:   +1-646-833-3417

     Ms. Mabel Zhang, Vice President
     Tel:   +1-310-954-1353

SOURCE China Sky One Medical, Inc.

Back to top



SOURCE China Sky One Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
2. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
3. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
4. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
5. China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
6. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
7. Varian Medical Systems to Exhibit Cancer Treatment and X-ray Imaging Technologies at China Med Exhibition
8. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
9. China Animal Welfare Law Under Review While 36,000 Dogs Culled
10. China-Biotics, Inc. Prices $69 Million Public Offering of Common Stock
11. Clifford Chance Advises Pfizer on Conditional Clearance in China of Its Merger with Wyeth
Post Your Comments:
(Date:12/1/2015)... Pa. , Dec. 1, 2015  Today, ... announced the launch of CareFront, a first-of-its-kind population ... patients diagnosed with cancer. Designed to be built ... diagnosed cancer patients with resources for their care ... The program also offers tools to help patients ...
(Date:12/1/2015)... , Dec. 1, 2015   Craneware, ... value cycle solutions, today announced the company will ... Pharmacy ChargeLink ® solution at the ... Midyear Clinical Meeting . The new features are ... process of monitoring and managing enterprise-wide pharmacy charges ...
(Date:12/1/2015)... 1, 2015  Booth #3506 – Claymount is featuring its ... meeting of the Radiological Society of North America ... year. Based in the Netherlands , Claymount ... Systems (NYSE: VAR ) and is one of the ... solid state automatic exposure control systems for controlling dose during ...
Breaking Medicine Technology:
(Date:12/1/2015)... Fla. (PRWEB) , ... December 01, 2015 , ... ... number of leadless pacemakers in the U.S. and is the only hospital in ... from the largest clinical data presentation of transcatheter pacing patients were revealed recently ...
(Date:12/1/2015)... ... December 01, 2015 , ... Growth in medical payments per workers’ ... in utilization of hospital and nonhospital care, according to a recent study by the ... Louisiana, 16th Edition , found medical payments per claim with more than seven days ...
(Date:12/1/2015)... ... December 01, 2015 , ... It’s official: Tattoo taboo is ... a number even greater among Millennials (a whopping one in three aged 18 to ... people who are dissatisfied with their ink. In fact, RealSelf , the world’s ...
(Date:12/1/2015)... ... December 01, 2015 , ... For many X-rays taken at ... accurate interpretation by the radiologist. The marking utensils are so small, however, they ... found a way to alleviate this problem. , He developed the patent-pending MARK ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... it has been selected as a finalist in this year’s Fierce Innovation Awards: ... Next IT Healthcare was recognized as a finalist in the category of Digital ...
Breaking Medicine News(10 mins):